Symproic Tablets 0.2mg drug use-results survey

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223931

Enrollment

350

Registered

2018-06-05

Start date

2018-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Induced Constipation

Interventions

investigational material(s) Generic name etc : Symproic Tablets 0.2mg (Naldemedine) INN of investigational material : Naldemedine Therapeutic category code : 235 Purgatives and clysters Dosage and Adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety, Efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026